Guelph, May 28, 2018 – Glysantis Inc., a privately held biotechnology company developing novel nanomedicines, announced today that it will be participating in business partnering meetings during the 2018 BIO International Convention, to be held in Boston on June 4-7, 2018.
Glysantis Inc. is one of 23 Ontario biotechnology companies selected to join the Ontario Trade Mission to the BIO International Convention.
Glysantis’ President & CEO, Phil Whiting, PhD, and Sr. Business Development Associate, Ricky Ghoshal, will be meeting with business development leaders from the biotech/pharma industry as well as investment professionals. The Company will be showcasing its NanoDendrix™ phytoglycogen nanoparticle platform and provide an update on its pre-clinical development programs in immunomodulation and drug delivery. Both programs present opportunities for scientific collaboration and strategic transactions.
Delegates interested in meeting with Glysantis can reach out to the Company via BIO’s One-on-one partnering system available through the conference website (http://convention.bio.org/partner/) or by reaching out to Company management directly.
Glysantis Inc., a wholly-owned subsidiary of Mirexus Biotechnologies Inc. (MBI), is a biotechnology company active in pre-clinical research & development of an innovative nanoparticle technology platform, NanoDendrix™, based on monodisperse nano-glycogen extracted from sweet corn. These naturally assembled nanoparticles are safe, non-toxic, fully biodegradable, easily modifiable and can be manufactured at scale. Glysantis’ lead programs are in vaccine biomanufacturing, immunomodulation and targeted drug delivery.
About BIO International Convention 2018:
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.